Advertisement

Topics

What's Next for Bristol-Myers Squibb After Its Opdivo Setback?

16:47 EDT 22 Aug 2017 | Topix

Mixed results for a study with Opdivo in treating first-line kidney cancer give reasons for concern. But how worried should investors really be? reported its checkpoint inhibitor Imfinzi failed to improve progression-free survival in a late-stage study targeting lung cancer.

Original Article: What's Next for Bristol-Myers Squibb After Its Opdivo Setback?

NEXT ARTICLE

More From BioPortfolio on "What's Next for Bristol-Myers Squibb After Its Opdivo Setback?"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Lung Cancer
Lung cancer is the uncontrolled cell growth in tissues of the lung. Originating in the lungs, this growth may invade adjacent tissues and infiltrate beyond the lungs. Lung cancer, the most common cause of cancer-related death in men and women, is respons...